Assembly Biosciences Reports $20.3 Million Q3 Loss; Cash Runway Into 2029

Assembly Biosciences reported third-quarter 2026 collaboration revenue of $3.0 million and a net loss of $20.3 million, compared with revenue of $10.8 million and a $9.2 million net loss a year earlier. Loss per share was $0.93, while cash, cash equivalents and marketable securities totaled $314.3…